FDA Approves Daratumumab and Hyaluronidase-Fihj With Chemo and Steroid for Multiple Myeloma

The FDA has granted approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro®, Janssen Biotech, Inc.) in combination with pomalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. "In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response," wrote Meletios A. Dimopoulos, MD, Professor and Chairman of the Department of C...
Continue reading

Triple-Negative Breast Cancer: Which is Better, Adjuvant Chemotherapy or Radiotherapy?

In patients who have been diagnosed with T1 N0 M0 triple-negative breast cancer (TNBC), age plays a role in whether chemotherapy or radiotherapy will lead to better outcomes for overall survival and breast cancer–specific survival (BCSS), according to the results of a cohort study now published in JAMA Network Open. The investigators, led by Zhen Zhai, MD, of the Department of Breast Surgery in the First Affiliated Hospital in the College of Medicine at Zhejiang University in Hangzhou, China, en...
Continue reading

CTC Count-Driven Treatment Improves Survival in HR-Positive, HER2-Negative Metastatic Breast Cancer

Using circulating tumor cell (CTC) count to determine whether chemotherapy or endocrine therapy is used improves survival outcomes compared with clinically determined treatment in patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, according to the results of the open-label, randomized phase 3 STIC CTC trial published today in JAMA Oncology. The investigators, led by François-Clément Bidard, MD, PhD, Professor of Medicine at the University of Paris-Sac...
Continue reading

Modern Radiation Therapy Doses for Early-Stage Hodgkin Lymphoma: Chelsea Pinnix, MD, PhD

While radiation therapy is an effective treatment for patients with early-stage favorable Hodgkin lymphoma, it also poses a risk of long-term toxicity to the surrounding organs and tissue. In a study recently published in JAMA Network Open, a team of researchers led by first author Chelsea Pinnix, MD, PhD, of MD Anderson Cancer Center, found that combined modality therapy consisting of ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) and contemporary radiation therapy (RT) demonstrated effic...
Continue reading

Modern Radiation Plus Chemo Effective and Safe for Early-Stage Hodgkin Lymphoma

According to the results of a new study, combined modality therapy consisting of ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) followed by contemporary radiation therapy (RT) was effective and safe in patients with early-stage favorable Hodgkin lymphoma, with low radiation doses delivered to at-risk organs. "While maximal efficacy is demonstrated with combined modality therapy, RT is often omitted in fear of late adverse effects," write the investigators, led by first author Chelsea C. Pi...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.